<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04914598</url>
  </required_header>
  <id_info>
    <org_study_id>SIM-372-ENDO-301</org_study_id>
    <nct_id>NCT04914598</nct_id>
  </id_info>
  <brief_title>A Phase Ⅲ Clinical Study of Combined Cisplatin Versus Placebo Combined With Intracavitary Cisplatin Injection in the Treatment of Malignant Pleural Effusions</brief_title>
  <official_title>A Randomized, Controlled, Double-blind, Multi-center Phase Ⅲ Registration Clinical Study of Combined Cisplatin Versus Placebo Combined With Intracavitary Cisplatin Injection in the Treatment of Malignant Pleural Effusions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu Simcere Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu Simcere Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Malignant Pleural Effusion or Ascites is a common complication of malignant tumor, The&#xD;
      objective of this study is to compare the efficacy of Endostar/cisplatin with&#xD;
      placebo/cisplatin in patients with malignant pleural effusion or ascites.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 31, 2021</start_date>
  <completion_date type="Anticipated">October 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Puncture/drainage-Free Survival, PuFS</measure>
    <time_frame>From the date of the end of experiment therapy to the next Puncture /drainage or death from any cause, up to 6 months</time_frame>
    <description>Compared with placebo combined with intracavitary cisplatin injection, use Puncture/drainage-Free Survival (Puncture/drainage-Free Survival, PuFS) as an indicator to evaluate Endo® combined with cisplatin intracavitary injection in the treatment of malignant pleural or ascites effusion Efficacy.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">290</enrollment>
  <condition>Malignant Pleural Effusion</condition>
  <arm_group>
    <arm_group_label>ENDOSTAR combined with cisplatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo combined with cisplatin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ENDOSTAR，cisplatin</intervention_name>
    <description>After sufficient puncture and drainage or drainage, use Endo® (45mg/time in thoracic cavity, 60mg/time in abdominal cavity) + cisplatin (40mg/time) intracavitary injection, administration on 1, 4, and 7 days, 3 times as a course of treatment</description>
    <arm_group_label>ENDOSTAR combined with cisplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo , cisplatin</intervention_name>
    <description>Placebo , cisplatin</description>
    <arm_group_label>Placebo combined with cisplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically or cytologically confirmed cancer of any primary tumor type, Patients&#xD;
             with Malignant Pleural Effusion or Ascites who remain poorly controlled after at least&#xD;
             one systemic antitumor therapy and at least one local therapy (intracavitary&#xD;
             administration of chemotherapeutic agents and/or biological response modulators, other&#xD;
             than cisplatin.)&#xD;
&#xD;
          2. At least a medium amount of malignant pleural effusion or ascites conformed by&#xD;
             confirmed by B ultrasound, Clinical judgment requires local therapy.&#xD;
&#xD;
          3. Karnofsky Performance Status ≥60&#xD;
&#xD;
          4. Life expectancy of at least 3 months&#xD;
&#xD;
          5. Adequate hematologic, cardiac, renal, and hepatic function&#xD;
&#xD;
          6. The serum pregnancy test of female subjects of childbearing age during the screening&#xD;
             period was negative; With a fertile female/male subjects must be willing to throughout&#xD;
             the study period (i.e., for the first time since the drug delivery to the end of the&#xD;
             study drug dosing after 90 days) to take reliable contraceptive methods, including but&#xD;
             not limited to: abstinence, male partners have accepted vasectomy, female&#xD;
             sterilization, intrauterine device effectively and effective birth control pills.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Participating in or receiving investigational treatment in another clinical trial&#xD;
             within 4 weeks prior to first dosing, or participating in a device clinical trial&#xD;
             within 4 weeks Evidence of bleeding diathesis, serious infection&#xD;
&#xD;
          2. Received systemic antitumor therapy or intraperitoneal drug therapy within 14 days of&#xD;
             the first intracavitary administration;&#xD;
&#xD;
          3. Endostatin, bevacizumab, Ramucirumab, and other antiangiogenic agents or cisplatin&#xD;
             were used for local therapy&#xD;
&#xD;
          4. Has not recovered from any adverse event due to any intervention to ≤1 prior to&#xD;
             initial administration (except for hair loss, hearing loss, and neurological or&#xD;
             endocrine disorders of ≤2 requiring alternative treatment)&#xD;
&#xD;
          5. Had undergone medium to major surgery other than diagnosis or biopsy within 28 days&#xD;
             prior to first administration, or who were expected to undergo major surgery during&#xD;
             the study period&#xD;
&#xD;
          6. Bilateral pleural effusion or enveloped pleural effusion or ascite&#xD;
&#xD;
          7. With severe COPD or a history of intestinal adhesions&#xD;
&#xD;
          8. uncontrolled primary brain tumor or central nerve metastatic tumor with significant&#xD;
             intracranial hypertension or neuropsychiatric symptoms&#xD;
&#xD;
          9. Active infections that require systemic treatment&#xD;
&#xD;
         10. Pregnant or lactating women&#xD;
&#xD;
         11. history of illness, treatment, or laboratory abnormality that may interfere with the&#xD;
             outcome of the study and prevent subjects from participating fully in the study, or&#xD;
             participation is not considered by the investigator to be in the subjects' best&#xD;
             interest.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shukui Qin, Doctor</last_name>
    <role>Study Chair</role>
    <affiliation>Shanghai East Hospital of Tongji University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jin Li, Doctor</last_name>
    <role>Study Chair</role>
    <affiliation>Shanghai East Hospital of Tongji University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiaoying Wang</last_name>
    <phone>18201936643</phone>
    <email>xiaoying.wang@simceregroup.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Xiaoying Wang</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Xiaoying Wang</last_name>
      <phone>18201936643</phone>
      <email>xiaoying.wang@simceregroup.com</email>
    </contact>
    <investigator>
      <last_name>Shukui Qin, doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jin Li, doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 27, 2021</study_first_submitted>
  <study_first_submitted_qc>May 31, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 4, 2021</study_first_posted>
  <last_update_submitted>May 31, 2021</last_update_submitted>
  <last_update_submitted_qc>May 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pleural Effusion, Malignant</mesh_term>
    <mesh_term>Pleural Effusion</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Endostar protein</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

